Objective. To investigate the diagnostic accuracy of RF as a test for RA in primary care and its impact on referral times using the Clinical Practice Research Datalink.
Introduction
RA is a destructive inflammatory joint disease. Bone oedema leading to erosions has been demonstrated as early as 4 weeks after symptom onset [1] and early referral of patients with suspected RA for treatment with DMARDS is advocated in order to prevent long-term joint damage and disability [25] . Many general practitioners (GPs) undertake investigations to support early diagnosis and guide referrals, and this may include testing for RF [6, 7] . RF has a pooled sensitivity of 69% (range 6573) and specificity of 85% (range 8288) [8] and has an established role in the classification of RA [9] . The National Institute for Health and Care Excellence (NICE) guidelines specifically advise against a delay in urgent referral of patients with persistent synovitis who have a negative RF [2] . However, RF results have been shown to influence referral decisions and GPs may use a negative test to exclude RA despite the presence of clinical features suggesting the disease [6, 10] . This may lead to a delay in diagnosis for patients with RF À disease and referral of patients with a false positive test and poor clinical evidence of disease.
Most studies on the diagnostic utility of RF have taken place in early arthritis clinics in secondary care where the pretest probability of RA is relatively high. Few studies have been conducted in general practice, where the pretest probability of RA is low [6, 10, 11] . However, most RF testing takes place in primary care [11] . It is important for GPs and patients to have information on the usefulness of RF in excluding RA or supporting referral. Our primary aim was to determine the diagnostic value of RF for RA in primary care by estimating likelihood ratios (LRs), sensitivity, specificity and predictive values using data from the UK Clinical Practice Research Datalink (CPRD). Our secondary aim was to determine the prognostic impact of the RF result on time to referral to secondary care.
Methods

Data source
The UK CPRD is the world's largest longitudinal primary care database, containing data for approximately 13.3 million individuals registered with 613 UK primary care practices. It has been found to be generally representative of the UK population [12] . GPs use a coded thesaurus of clinical terms, called Read codes, to record clinical features, laboratory tests and results, diagnoses and other information. We had access to Read codes but not to supplemental free text. The study was approved by the Independent Scientific Advisory Committee for the CPRD (protocol number 10_150RA2).
Study population
The study period ran from 1 January 2000 to 31 December 2010. Patients had contributed at least 12 months of research standard data to the CPRD before the date of their first RF test and at least 2 years of follow-up data subsequently, unless they died during the 2 years of follow-up, in which case they were included to date of death.
We identified all RF tests recorded as an RF titre or a Read code for a positive or negative RF test in the CPRD records of permanently registered patients 516 years of age between 1 January 2000 and 31 December 2008. The first test in each patient's record was identified and patients with a record of an RF test before the study period were excluded. During the course of the study we observed a bias in the way RF was recorded in the CPRD, with tests being more likely to be recorded if positive [13] and negative tests either being recorded without an RF titre or not recorded at all, possibly because positive tests are more clinically meaningful to GPs. Where there was evidence of preferential data recording, missing data were considered to be missing not at random (MNAR) [14, 15] . In order to minimize the impact of selection bias thus introduced, we stratified the data by general practice and calendar year (practice-years) and excluded practice-years where the proportion of positive tests was >20%. This cut-off was based on a study by Miller et al. [11] that found that the mean percentage of positive RF tests in primary care was 6.3%. Based on a comparison of the distribution of the percentage of positive RF tests against that for the study by Miller et al. [13] , we considered that it was likely that practice-years with >20% of positive tests were likely to be preferentially recording positive tests and were thus MNAR; the full methods of this investigation are described elsewhere. The remaining tests were from practice-years where missing data were likely to be missing at random, allowing for a complete case analysis to be conducted with a lower risk of selection bias [15] . From this dataset we then selected tests where a test result or RF titre was available.
We excluded patients with a diagnosis of RA >3 months before their first RF test, those with pre-existing CTDs (SLE, PM/DM, SSc and SS) or those with psoriasis or IBD at any time.
Classification of RF test results
RF results were classified as positive if the recorded titre was above the upper value of the normal range (UNR) in the electronic test record or there was a Read code for a positive RF in the medical records. Where normal ranges were not recorded, we assumed that a practice had sent all RF tests to the same laboratory during that calendar year and imputed the UNR value as the mode value stratified by year and general practice. Due to the variation in the UNR cut-off, we calculated the difference between the RF titre and the UNR cut-off value in order to investigate the relationship between RF titre and RA diagnosis. We denoted this as the offset RF value.
Identifying cases of RA
We searched the medical records of the study population for patients with a diagnosis of RA up to 2 years following the first RF test. We based our case identification on the algorithm validated by Thomas et al. [16] . Those with a Read code for seropositive or erosive disease and those with at least one prescription for a DMARD within 2 years of diagnosis were classified as cases of RA; those with more than one record of RA diagnosis but without any prescriptions for DMARDs were classified as probable RA. Identification of cases of RA was undertaken without knowledge of the RF result. The date of RA diagnosis was taken as the first record of RA or the date of the first prescription for a DMARD, whichever was earlier.
Covariate identification
For each patient in the study population we determined smoking status and BMI nearest to their first RF test. The presence of pre-existing diabetes mellitus was determined using a previously described algorithm [17] .
www.rheumatology.oxfordjournals.org Pre-existing thyroid disease or cancer in the year before diagnosis was determined. Individual socio-economic status was not available for every patient in the study population, therefore we used the general practice Index of Multiple Deprivation score quintile, where a score of 5 indicates the highest level of deprivation.
Time from RF test to hospital referral or attendance
We identified all records of referral, outpatient clinic attendance and inpatient discharge summaries that were coded as having a rheumatology specialty and determined the earliest date of first contact with rheumatology. Specialty-specific data are inconsistently recorded in the CPRD, therefore we identified all records of hospital referral, outpatient clinic attendance, letters and inpatient discharge summaries, and determined the earliest date of contact with any hospital department.
Statistical analyses
All analyses were undertaken using STATA Statistical Software version 12 (StataCorp,College Station, TX, USA). We calculated the positive and negative LRs, sensitivity, specificity and predictive values of RF for a diagnosis of RA in patients with positive or negative RF tests. We performed sensitivity analyses excluding patients with probable RA and to determine the effect of classifying a patient as having RA if the RF value was equal to or above the UNR value. We performed a sensitivity analysis of all test data in the original study population, including data that were considered to be MNAR, to quantify the impact of this on the measures of diagnostic accuracy. Modified Poisson regression models with robust variance estimates [18] were used to calculate the relative risk (RR) for a diagnosis of RA within 2 years associated with increasing offset RF titre values.
The distribution of baseline characteristics of patients with positive and negative RF test results was compared using chi-square tests. Modified Poisson regression models [18] were used to calculate adjusted RR characteristics found to be associated with a positive RF test, including co-morbidity and records of musculoskeletal symptoms in the 6 months before the test. Variables were selected for inclusion in the model using forwards stepwise Poisson regression models set to accept variables at a significance of P 4 0.2 [19] . Cox proportional hazards models were used to calculate the hazard ratio of death within 2 years of first RF test. We constructed KaplanMeier failure curves to investigate the effect of a positive and negative RF result on referral times to a rheumatologist and to any hospital contact following the first RF test. Log-rank tests were used to determine the equality of the failure curves in those with positive and negative RF tests.
Results
There were 91 293 eligible first RF tests with a test result recorded in the CPRD during the study period. We excluded 28 857 tests from practice-years where there was evidence that missing data were MNAR or there was an exclusion diagnosis present, resulting in a final study population of 62 436 RF tests. The number of eligible tests that were included increased from 2234 in 2000 to 9167 in 2008. This is likely to reflect the change from manual to automatic recording of test results. There were 4697 (7.5%) positive and 57 739 (92.5%) negative tests. Of these tests, 42 545 (68.1%) were undertaken in females. Forty-four patients (0.08%) with a negative first RF test had a subsequent positive test within 2 years of their first test. Table 1 shows the baseline characteristics of the study population stratified by RF test result. The mean age of patients who were RF + was significantly greater than those who were RF À ; the mean difference was 6.0 years (95% CI 5.6, 6.5). Current smokers and those with unknown smoking status were more likely to have a positive test result relative to non-smokers. Those with a BMI <20 had an increased risk relative to those with a BMI of 2024.
A total of 1091 patients died within 2 years of their first RF test, of whom 186 (17.1%) had a positive result. The adjusted HR for death within 2 years of the first RF result was 1.5 (95% CI 1.3, 1.8) after adjustment for age, sex and all variables found to be associated with a positive RF test.
Diagnostic accuracy of RF testing
There were 1740 incident cases of RA; 1285 of these had a record of a DMARD prescription after their date of RA diagnosis. Four hundred and fifty-five had no DMARD prescriptions within 2 years and were classified as probable RA. One thousand and five (57.8%) of the RA cases had a positive first RF result and 735 (42.2%) a negative result. Of those without a diagnosis of RA within 2 years, 3692 (6.1%) had a positive RF test and 57 004 (93.9%) a negative RF test. Table 2 shows the results of the diagnostic accuracy analysis and Table 3 demonstrates that the RR for a diagnosis of RA increased with increasing RF titre.
Referral to secondary care
Of the 62 436 patients with a first RF test during the study period, 1695 had a referral to rheumatology prior to the date of their first RF and were excluded from the analysis of referral times, leaving 60 741 eligible patients. Fig. 1 shows the KaplanMeier failure curves for contact with a rheumatology department in the 2 years following the first RF test. The KaplanMeier curve illustrates that when contact with rheumatology services occurred, it tended to be a short time after the first RF test. A higher proportion of patients with an RF + test were referred to rheumatology within 2 years of testing (P < 0.0001). Three thousand nine hundred and twenty-four (86.9%) of the patients with an RF + test and 44 335 (78.9%) of those with an RF À test had a record of any hospital contact within 2 years of their first RF test. Fig. 2 shows the KaplanMeier curve for contact with any hospital department in the 2 years following the first RF test. A higher proportion of patients with an RF + 
Discussion
We report the diagnostic utility of RF in a large electronic dataset of primary care patients representing $8.4% of the UK population. RF was found to be highly specific, with a moderately good positive LR of 9.5 (95% CI 9.0, 10.0). However, its sensitivity was low and the negative LR was poor at 0.5 (95% CI 0.4, 0.5). The first RF test was positive for 57.8% incident cases of RA and higher titres were associated with a diagnosis of RA. We demonstrated an increase in the RR of a positive test with increasing age and a higher risk of death with a positive RF result (RR 1.5). We demonstrated a delay in referral of patients with a negative RF result to rheumatology and to hospital in general, although 78.986.9% of patients undergoing testing were referred for hospital review in the 2 years following the test. The main strength of the study is that it is based in a primary care population, where most RF requests take place, and is the largest study to date of the utility of RF as a test for RA in this setting. The CPRD is an observational dataset consisting of records kept by GPs in day-to-day patient management. It is a valuable resource for large epidemiological studies, but has limitations, for example, the loss of patients to follow-up when they change practice and the lack of valid data prior to their entry into the database. Diagnoses are recorded using Read codes, and consequently definition of cases may be hampered by variation in recording methods. We identified cases of RA using an algorithm based on that validated by Thomas et al. [16] with a sensitivity of 84% (95% CI 73%, 94%) and a specificity of 86% (95% CI 72%, 92%). These figures suggest that a number of cases with Read codes for RA might be misclassified, introducing potential bias in our results. The sensitivity analyses (Table 2) showed that the LRs from the primary analysis were robust in excluding probable cases of RA, but that changes to the definition of a positive RF test [sensitivity analysis (see footnote b in Table 2 ), excludes probable cases of RA] and the inclusion of data that were considered to be MNAR [sensitivity analysis (see footnote d in Table 2 ), includes all original data (including data considered to be MNAR)] resulted in a substantial decrease in the positive LR. When data that were considered to be MNAR were included, the proportion of positive tests in the study population increased from 7.5% to 19.5% and the proportion of negative tests decreased from 92.5% to 80.5%, resulting in a reduction in the positive LR but a stable negative LR. Our analysis demonstrates the preferential recording of positive tests in the CPRD. The change from manual to automatic coding of test results in the CPRD was reflected in the increase in eligible tests from the beginning to the end of the study period. However, we do not have the practice-specific data regarding the dates of this change. Since we would expect 6.3% of RF tests in primary care to be positive, we have shown that the inclusion of data that are MNAR gives rise to the analysis of a biased population.
We acknowledge that people diagnosed with RA on clinical grounds and referred directly without RF testing in primary care were not included and that not all study participants were assessed by a rheumatologist for the presence or absence of RA. This may have introduced detection bias because RF + patients were more likely to be referred to hospital and RF À patients might have not been referred during the 2 year follow-up period, resulting in a higher specificity than expected.
Forty-two per cent of patients diagnosed with RA had a negative first RF test in primary care, which is comparable to a cohort of 1892 patients with new RA where 37% of RF tests were negative [20] . In Table 4 we compare our results with those of a meta-analysis [8] and pooled values from a systematic review [21] . The sensitivity of RF was lower in early arthritis studies, suggesting poorer utility earlier in the disease and consistent with our results. A poor negative LR is reported throughout the literature. Our finding that a positive RF result is associated with an increased risk of death is in keeping with other population studies [22] , although the risk estimate might be confounded by the development of co-morbidity after diagnosis. In general, a positive LR > 10 and a negative LR < 0.1 are considered to provide strong evidence to rule in or rule out diagnoses, respectively [22, 23] . This study and previous analyses [8, 21] have demonstrated the positive LR for RF to be <10 and the negative LR to be >0.1, indicating moderate performance ruling in and poor performance ruling out RA. While higher titres are   FIG. 2 KaplanMeier failure curve for contact with any hospital department in the 2 years following first RF test, stratified by RF test result www.rheumatology.oxfordjournals.org associated with a greater likelihood of the patient having RA, a negative test does not exclude it.
Only 2.8% of patients undergoing RF testing had a final diagnosis of RA, suggesting that RF is used to screen patients presenting with musculoskeletal symptoms rather than to support a diagnosis in patients with specific features of RA. This is in keeping with a recent UK study of RF requests in primary care, where 5.8% of tests were positive and 4% had an eventual diagnosis of RA [11] . According to the 2010 ACR/EULAR criteria [9] , RF has an important role in the diagnosis of RA. The low diagnostic yield demonstrated in primary care is largely due to incorrect use or interpretation. Up to 87% of patients undergoing RF testing were referred to hospital and a positive RF was associated with a much reduced time to first hospital contact compared with those with a negative RF test. This may be either because patients with an RF + result are more unwell and referred on clinical grounds or that an RF result influences referral decisions. The main question raised in our study is whether an RF test should be requested and how it should be interpreted in primary care. These are also relevant questions for other immunological tests such as ANA and ACPA. It has been suggested that ACPA might be useful as a screening test for RA, because of its high specificity and similar sensitivity to RF [24] , and used to guide referrals in patients with suspected inflammatory joint disease [25] . However, if used indiscriminately in patients with a low pretest probability of RA, neither a positive RF nor a positive ACPA test result affects clinical probabilities sufficiently to secure a diagnosis [26] , and its utility as a test would be hampered by the same problems of overuse and overinterpretation.
